Lindner, Sarah http://orcid.org/0000-0002-9985-1205
Miltiadous, Oriana http://orcid.org/0000-0002-1571-3893
Ramos, Ruben J. F.
Paredes, Jenny http://orcid.org/0009-0009-6072-8267
Kousa, Anastasia I. http://orcid.org/0000-0002-4550-0389
Dai, Anqi
Fei, Teng http://orcid.org/0000-0001-7888-1715
Lauder, Emma
Frame, John
Waters, Nicholas R. http://orcid.org/0000-0002-9035-2143
Sadeghi, Keimya
Armijo, Gabriel K.
Ghale, Romina
Victor, Kristen http://orcid.org/0009-0000-7948-3698
Gipson, Brianna
Monette, Sebastien http://orcid.org/0000-0003-2841-6887
Russo, Marco Vincenzo
Nguyen, Chi L.
Slingerland, John
Taur, Ying http://orcid.org/0000-0002-6601-8284
Markey, Kate A.
Andrlova, Hana
Giralt, Sergio
Perales, Miguel-Angel http://orcid.org/0000-0002-5910-4571
Reddy, Pavan http://orcid.org/0000-0001-7264-8429
Peled, Jonathan U. http://orcid.org/0000-0002-4029-7625
Smith, Melody
Cross, Justin R.
Burgos da Silva, Marina
Campbell, Clarissa http://orcid.org/0000-0002-1918-0318
van den Brink, Marcel R. M. http://orcid.org/0000-0003-0696-4401
Article History
Received: 28 January 2023
Accepted: 22 January 2024
First Online: 1 March 2024
Competing interests
: M.-A.P. reports honoraria from Adicet, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Syncopation, VectivBio AG and Vor Biopharma; he serves on DSMBs for Cidara Therapeutics, Medigene and Sellas Life Sciences, and the scientific advisory board of NexImmune; he has ownership interests in NexImmune and Omeros; and he has received institutional research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics and Novartis. K.A.M. holds equity and is on the advisory board of Postbiotics Plus, and has consulted for Incyte. J.U.P. reports research funding, intellectual property fees and travel reimbursement from Seres Therapeutics, and consulting fees from Da Volterra, CSL Behring and MaaT Pharma; he serves on the Advisory board of and holds equity in Postbiotics Plus Research; and he has filed intellectual property applications related to the microbiome (reference numbers 62/843,849, 62/977,908 and 15/756,845). M.R.M.v.d.B. has received research support and stock options from Seres Therapeutics, and stock options from Notch Therapeutics and Pluto Therapeutics; he has received royalties from Wolters Kluwer; he has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, Vor Biopharma, Rheos Medicines, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Ceramedix, Lygenesis, Pluto Therapeutics, GlaskoSmithKline, Da Volterra, Thymofox, Garuda, Novartis (Spouse), Synthekine (Spouse), Beigene (Spouse) and Kite (Spouse); he has IP Licensing with Seres Therapeutics and Juno Therapeutics; and he holds a fiduciary role on the Foundation Board of DKMS (a nonprofit organization). Memorial Sloan Kettering has institutional financial interests relative to Seres Therapeutics. The remaining authors declare no competing interests.